| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02542dbae5d862aec5709db5dc5fcf9c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-056 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-056 |
| filingDate |
1997-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3df23472d24e6e9e4416157bf752d6e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e85b32108e72762e12f91cfefdafe829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76c52ca276fb0097057884d08e8719ae |
| publicationDate |
2003-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1302474-A1 |
| titleOfInvention |
Monocyclic L-nucleosides, analogs and uses thereof |
| abstract |
Novel monocyclic L-nucleoside compounds have the generalnformula (I). Embodiments of these compounds are contemplatednto be useful in treating a wide variety of diseases includingninfections, infestations, neoplasms, and autoimmune diseases.nViewed in terms of mechanism, embodiments of the novelncompounds show immunomodulatory activity, and are expected tonbe useful in modulating the cytokine pattern, includingnmodulation of Th1 and Th2 response. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008153385-A1 |
| priorityDate |
1996-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |